HWAM
AMLX icon

Hennion & Walsh Asset Management’s Amylyx Pharmaceuticals AMLX Stock Holding History

Hennion & Walsh Asset Management’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-47,898
Closed -$651K – 929
2025
Q3 		$651K Sell
47,898
-8,933
-16% -$84.1K 0.02% 634
2025
Q2 		$364K Sell
56,831
-26,405
-32% -$128K 0.01% 769
2025
Q1 		$295K Sell
83,236
-7,383
-8% -$26.3K 0.01% 765
2024
Q4 		$343K Sell
90,619
-23,915
-21% -$113K 0.02% 728
2024
Q3 		$371K Sell
114,534
-4,449
-4% -$10K 0.02% 691
2024
Q2 		$226K Buy
118,983
+6,116
+5% +$11.9K 0.01% 784
2024
Q1 		$321K Buy
112,867
+27,937
+33% +$365K 0.02% 671
2023
Q4 		$1.25M Buy
84,930
+35,364
+71% +$542K 0.07% 352
2023
Q3 		$908K Buy
49,566
+14,427
+41% +$305K 0.06% 382
2023
Q2 		$758K Buy
35,139
+14,718
+72% +$398K 0.04% 424
2023
Q1 		$599K Buy
20,421
+3,465
+20% +$120K 0.04% 470
2022
Q4 		$627K Buy
+16,956
New +$602K 0.04% 450

Other funds holding AMLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Hennion & Walsh Asset Management's AMLX Position: Q4 2025 in Review

Hennion & Walsh Asset Management sold out of Amylyx Pharmaceuticals (AMLX) in Q4 2025, closing a stake of 47,898 shares — an estimated $651K sold.

Hennion & Walsh Asset Management first reported a position in AMLX in Q4 2022 and held it in 12 quarters. The position peaked at $1.25M in Q4 2023. 179 funds tracked by Wall St. Rank hold AMLX as of Q4 2025.

  • Hennion & Walsh Asset Management reported no remaining Amylyx Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Hennion & Walsh Asset Management sold 47,898 Amylyx Pharmaceuticals shares in Q4 2025, an estimated $651K.
  • Hennion & Walsh Asset Management first reported a position in Amylyx Pharmaceuticals in Q4 2022 and held it in 12 quarters.
  • Hennion & Walsh Asset Management's Amylyx Pharmaceuticals position peaked at $1.25M in Q4 2023.
  • 179 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q4 2025.

Based on Hennion & Walsh Asset Management's 13F filing for Q4 2025, filed 14 Jan 2026.